title: Postantibiotic effect of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile.
abstract: Fidaxomicin (FDX), a narrow-spectrum antibiotic recently shown to be superior to vancomycin in providing sustained clinical response to Clostridium difficile infection, was investigated along with its major metabolite, OP-1118, with regard to their postantibiotic effects (PAE). FDX was found to have a prolonged PAE (10 h versus ATCC strains and 5.5 h versus a clinical isolate), and OP-1118's PAE was longer than that of the standard comparator, vancomycin (3 versus 0 to 1.5 h, respectively).
authors.affiliation: Optimer Pharmaceuticals, Inc., 10110 Sorrento Valley Rd., Suite C, San Diego, CA 92121, USA. fbabakhani@optimerpharma.com
authors.forename: Farah
authors.initials: F
authors.lastname: Babakhani
authors.forename: Abraham
authors.initials: A
authors.lastname: Gomez
authors.forename: Nikki
authors.initials: N
authors.lastname: Robert
authors.forename: Pamela
authors.initials: P
authors.lastname: Sears
mesh_terms: D000617:Aminoglycosides / Q000378:metabolism / Q000494:pharmacology*; D000900:Anti-Bacterial Agents / Q000378:metabolism / Q000494:pharmacology*; D016360:Clostridioides difficile / Q000187:drug effects*; D000077732:Fidaxomicin; D008826:Microbial Sensitivity Tests
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; C561044:OP-1118; D000077732:Fidaxomicin